Linayork M 500 Tablet is a combination oral antidiabetic medication containing Metformin 500 mg and Linagliptin 2.5 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, prolongs the activity of incretin hormones, which increase insulin secretion and decrease glucagon release in a glucose-dependent manner. The synergistic effect of these agents helps achieve better glycemic control compared to monotherapy. Linayork M 500 is recommended as an adjunct to diet and exercise to improve glycemic parameters in patients inadequately controlled on metformin alone or those requiring dual therapy. It is generally well tolerated; however, common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, primarily attributed to metformin. Linagliptin is associated with a low risk of hypoglycemia when used as monotherapy. Caution is advised in patients with renal impairment, hepatic dysfunction, or heart failure. Regular monitoring of blood glucose levels and renal function is recommended during therapy. Linayork M 500 should be prescribed and used under medical supervision to optimize therapeutic outcomes and minimize potential risks.